Gilead Sciences adds fuel to fire in hep C pricing battle with Anthem deal

January 9, 2015 4:57 PM

4 0

Gilead Sciences adds fuel to fire in hep C pricing battle with Anthem deal

Gilead Sciences ($GILD) has not wasted any time in its hep C pricing war with AbbVie ($ABBV). Weeks after the Illinois drugmaker struck an exclusive deal with Express Scripts ($ESRX) for its Viekira cocktail, Gilead inked a pact with the PBM's biggest rival, CVS Health ($CVS), to make its Harvoni and Sovaldi available on the payer's main drug list.

Now, Gilead is joining forces with Anthem ($ANTM), the biggest provider of health coverage to U.S. businesses and Express Scripts' largest customer, to make Harvoni the primary option for patients, adding fuel to the fire and setting the stage for a hep C showdown.

Read more

To category page

Loading...